A Phase 2a Study to Test the Safety and Effectiveness of MK-8690 Injections for Adults With Moderate to Severe Ulcerative Colitis

What this Trial Is About

Researchers are evaluating MK-8690 in adults with moderately to severely active ulcerative colitis to see if it is more effective than a placebo in helping participants achieve clinical remission by Week 12. This is a Phase 2a randomized, double-blind, placebo-controlled study focused on treatment outcomes for ulcerative colitis, sponsored by Merck Sharp & Dohme LLC. Participants will receive MK-8690 or a placebo through subcutaneous injections for 12 weeks during the first period. Those who do not respond to treatment will receive MK-8690 for an additional 12 weeks in the second period. Participants who respond to treatment in either period will continue receiving MK-8690 injections for up to about 42 more weeks to further assess the treatment. During the study, participants will have regular assessments including evaluations of clinical remission using the Modified Mayo Score at Week 12. Researchers will monitor adverse events, treatment discontinuations, clinical responses, endoscopic improvements, and mucosal healing over approximately 12 months. The study involves randomized treatment assignments and triple blinding to ensure objective results, with a total participation time spanning from initial screening through up to about a year of follow-up.

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)